Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Letermovir in ESKD
NCT07101055Phase 1Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms). Primary endpoint: Area Under the plasma concentration-time Curve at 48 hours. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07101055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101055.